Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

Lantheus secures CMS reimbursement milestones for PYLARIFY TruVu through 2029.

What the company is saying

Lantheus Holdings, Inc. highlights the Centers for Medicare & Medicaid Services' (CMS) final rule maintaining separate payment for qualifying diagnostic radiopharmaceuticals, positioning this as a regulatory win for its portfolio. The company underscores that PYLARIFY TruVu will receive Transitional Pass-Through (TPT) payment status through September 30, 2029, and has been assigned permanent HCPCS code A9613 effective October 1, 2026, which they frame as providing reimbursement certainty and supporting hospital adoption. Amanda Morgan, Chief Commercial Officer, is quoted to reinforce the narrative that these regulatory decisions will enhance patient access to advanced imaging and inform prostate cancer care. The announcement also details the broader commercial portfolio, including PYLARIFY, PYLARIFY TruVu, and NEURACEQ, and references a pipeline spanning oncology, neurology, and cardiology. The company presents these milestones as evidence of ongoing support for policies enabling reimbursement and access as new diagnostics reach clinical use. Safety information is included, with adverse reactions in clinical studies occurring at rates of ≤2%, and a single delayed hypersensitivity event at 0.2%. The tone is confident and focuses on regulatory progress rather than financial or operational results.

What the data suggests

The CMS final rule secures separate payment for qualifying diagnostic radiopharmaceuticals, directly benefiting Lantheus' PYLARIFY TruVu, which will maintain TPT payment status through September 30, 2029. The assignment of permanent HCPCS code A9613, effective October 1, 2026, will streamline billing and reimbursement for providers. These regulatory milestones are concrete and near-term, with the TPT period covering a full three years from the code's effective date. The most common adverse reactions to PYLARIFY and PYLARIFY TruVu in clinical studies were headaches, dysgeusia, and fatigue, each at a rate of ≤2%, with a single delayed hypersensitivity reaction reported at 0.2%. No financial metrics, revenue projections, or adoption rates are disclosed, so the direct financial impact of these regulatory wins cannot be quantified from this announcement. The company's commercial portfolio and pipeline breadth are stated, but without operational or financial performance data. The evidence supports realised regulatory progress, but does not allow assessment of financial trajectory or market uptake.

Analysis

The announcement is primarily factual, detailing the confirmation of CMS Transitional Pass-Through (TPT) payment status for PYLARIFY TruVu through September 2029 and the assignment of a permanent HCPCS code effective October 2026. These are realised regulatory milestones, not aspirational claims. The tone is positive, emphasizing improved reimbursement certainty and patient access, but these statements are proportionate to the regulatory achievements disclosed. There is only one forward-looking statement about supporting future policies and access, which is generic and not overhyped. No large capital outlay or long-dated, uncertain returns are mentioned. However, the absence of any financial or profitability metrics (revenue, EBITDA, net income) means the true_signal cannot exceed weak_positive, as investors cannot assess the financial impact of these regulatory wins. The gap between narrative and evidence is minimal, with most claims directly supported by regulatory facts.

Risk flags

• ●Execution risk remains around the adoption of PYLARIFY TruVu by hospitals and payers, as the announcement notes the need for payers to add HCPCS coding to their systems and for customers to adopt the product. Delays or failures in these steps could limit the realised benefit of the regulatory milestones.
• ●Operational risk is present in the technology transfer and FDA approval process for each PET manufacturing facility (PMF) in the company's network, as disruptions could affect supply chain continuity and market availability of PYLARIFY TruVu.
• ●There is a lack of disclosed financial data, such as revenue, margin, or adoption rates, so investors cannot assess the magnitude of potential financial upside or downside from these regulatory changes. This limits visibility into the true economic impact.

Bottom line

Lantheus has achieved key regulatory milestones for PYLARIFY TruVu, securing CMS Transitional Pass-Through payment status through September 2029 and a permanent HCPCS code effective October 2026, which should facilitate reimbursement and provider uptake. These are concrete, near-term regulatory wins, but the announcement does not quantify the financial impact or provide adoption metrics, leaving the scale of benefit unclear. The company faces execution risks in ensuring payers and hospitals implement the new coding and in maintaining uninterrupted supply through its manufacturing network. Safety data is transparent, with adverse reactions occurring at low rates (≤2% for common events, 0.2% for delayed hypersensitivity). For investors, this update signals regulatory momentum but lacks the financial disclosure needed to assess earnings potential. The most important takeaway is that while reimbursement certainty is improved, the translation into revenue and profit remains to be demonstrated in future disclosures.

Announcement summary

(NASDAQ: LNTH) Lantheus Holdings, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule maintains separate payment for qualifying diagnostic radiopharmaceuticals. CMS confirmed that PYLARIFY TruVu (piflufolastat F 18) injection will receive Transitional Pass-Through (TPT) payment status through September 30, 2029, reflecting the full three-year TPT period available in the hospital outpatient setting. PYLARIFY TruVu has been assigned permanent Healthcare Common Procedure Coding System (HCPCS) code A9613, effective October 1, 2026, which will facilitate billing and reimbursement for providers. Amanda Morgan, Chief Commercial Officer of Lantheus, stated that the CMS final rule is an important step in supporting patient access to advanced diagnostic imaging and the adoption of innovative radiopharmaceutical technologies. She noted that the confirmation of TPT status for the full three-year period and the assignment of a permanent HCPCS code provides additional reimbursement certainty for hospitals and helps ensure patients can benefit from PSMA PET imaging for prostate cancer care. Lantheus' commercial radiodiagnostic portfolio includes PYLARIFY, PYLARIFY TruVu, and NEURACEQ (florbetaben F 18), as well as a broad pipeline of diagnostic radiopharmaceutical candidates across oncology, neurology, and cardiology. The company continues to support policies that enable appropriate reimbursement and patient access as new diagnostic radiopharmaceuticals reach clinical practice. PYLARIFY and PYLARIFY TruVu are indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer who are candidates for initial definitive therapy or have suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. The most frequently reported adverse reactions in clinical studies were headaches, dysgeusia, and fatigue, occurring at a rate of ≤2%. A delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions. Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway may result in changes in uptake of PYLARIFY and PYLARIFY TruVu in prostate cancer, but the effect of these therapies on performance has not been established. Lantheus is headquartered in Massachusetts with offices in Canada, Germany, Sweden, Switzerland, and the United Kingdom.

Disagree with this article?